{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:54:02Z","timestamp":1786985642393,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD) are leading neurodegenerative disorders marked by protein aggregation, with AD featuring amyloid-beta (A\u03b2) and tau proteins, and PD alpha-synuclein (\u03b1Syn). Dementia with Lewy bodies (DLB) often presents with a mix of these pathologies. This study explores naturally occurring autoantibodies (nAbs), including Immunoglobulin (Ig)G, IgM, and IgA, which target \u03b1Syn, A\u03b2 and tau to maintain homeostasis and were previously found altered in AD and PD patients, among others.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main text<\/jats:title>\n                    <jats:p>We extended this investigation across AD, PD and DLB patients investigating both the affinities of IgGs and levels of IgGs, IgMs and IgAs towards \u03b1Syn, A\u03b2 and tau utilizing chemiluminescence assays. We confirmed that AD and PD patients exhibited lower levels of high-affinity anti-A\u03b2 and anti-\u03b1Syn IgGs, respectively, than healthy controls. AD patients also showed diminished levels of high-affinity anti-\u03b1Syn IgGs, while anti-tau IgG affinities did not differ significantly across groups. However, DLB patients exhibited increased anti-\u03b1Syn IgG but decreased anti-\u03b1Syn IgM levels compared to controls and PD patients, with AD patients showing a similar pattern. Interestingly, AD patients had higher anti-A\u03b2 IgG but lower anti-A\u03b2 IgA levels than DLB patients. DLB patients had reduced anti-A\u03b2 IgM levels compared to controls, and anti-tau IgG levels were lower in AD than PD patients, who had reduced anti-tau IgM levels compared to controls. AD patients uniquely showed higher anti-tau IgA levels. Significant correlations were observed between clinical measures and nAbs, with negative correlations between anti-\u03b1Syn IgG affinity and levels in DLB patients and a positive correlation with anti-\u03b1Syn IgA levels in PD patients. Disease-specific changes in nAb levels and affinity correlations were identified, highlighting altered immune responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study reveals distinctive nAb profiles in AD, DLB, and PD, pinpointing specific immune deficiencies against pathological proteins. These insights into the autoreactive immune system\u2019s role in neurodegeneration suggest nAbs as potential markers for vulnerability to protein aggregation, offering new avenues for understanding and possibly diagnosing these conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-024-03293-3","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T01:40:11Z","timestamp":1733190011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Autoantibody profiles in Alzheimer\u00b4s, Parkinson\u00b4s, and dementia with Lewy bodies: altered IgG affinity and IgG\/IgM\/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns"],"prefix":"10.1186","volume":"21","author":[{"given":"Luisa","family":"Knecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Dalsb\u00f8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja Hviid","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Pilchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Alexander","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Winge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Salvesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Mette","family":"Hejl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemette","family":"L\u00f8kkegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen G","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Aznar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"Waldemar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Brudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Folke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"3293_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14:32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5.","journal-title":"Mol Neurodegener"},{"key":"3293_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R. Goedert, \u03b1-Synuclein in Lewy bodies. Nature. 1997;388:839\u201340. https:\/\/doi.org\/10.1038\/42166.","journal-title":"Nature"},{"key":"3293_CR3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jnen\/nlw070","volume":"75","author":"DH Hepp","year":"2016","unstructured":"Hepp DH, Vergoossen DLE, Huisman E, Lemstra AW, Bank NB, Berendse HW, Rozemuller AJ, Foncke EMJ, Van De Berg WDJ. Distribution and load of amyloid-b pathology in Parkinson disease and dementia with lewy bodies. J Neuropathol Exp Neurol. 2016;75:936\u201345. https:\/\/doi.org\/10.1093\/jnen\/nlw070.","journal-title":"J Neuropathol Exp Neurol"},{"key":"3293_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1212\/WNL.62.1.160","volume":"62","author":"KA Jellinger","year":"2004","unstructured":"Jellinger KA, Corey-Bloom J, Merdes AR, Hansen LA. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies [3] (multiple letters). Neurology. 2004;62:160. https:\/\/doi.org\/10.1212\/WNL.62.1.160.","journal-title":"Neurology"},{"key":"3293_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neulet.2010.09.036","volume":"486","author":"H Fujishiro","year":"2010","unstructured":"Fujishiro H, Iseki E, Higashi S, Kasanuki K, Murayama N, Togo T, Katsuse O, Uchikado H, Aoki N, Kosaka K, Arai H, Sato K. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci Lett. 2010;486:19\u201323. https:\/\/doi.org\/10.1016\/j.neulet.2010.09.036.","journal-title":"Neurosci Lett"},{"key":"3293_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"TF Outeiro","year":"2019","unstructured":"Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, Donaghy P, Morris C, Taylor J-P, Thomas A, Attems J, McKeith I. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14:5. https:\/\/doi.org\/10.1186\/s13024-019-0306-8.","journal-title":"Mol Neurodegener"},{"key":"3293_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/alzrt5","volume":"1","author":"TE Golde","year":"2009","unstructured":"Golde TE, Miller VM. Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer\u2019s and other neurodegenerative diseases. Alzheimers Res Ther. 2009;1:5. https:\/\/doi.org\/10.1186\/alzrt5.","journal-title":"Alzheimers Res Ther"},{"key":"3293_CR8","doi-asserted-by":"publisher","unstructured":"Hartl FU. Protein Misfolding Dis Annu Rev Biochem. 2017;86:21\u20136. https:\/\/doi.org\/10.1146\/annurev-biochem-061516-044518.","DOI":"10.1146\/annurev-biochem-061516-044518"},{"key":"3293_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1080\/00207454.2017.1286339","volume":"127","author":"N Sami","year":"2017","unstructured":"Sami N, Rahman S, Kumar V, Zaidi S, Islam A, Ali S, Ahmad F, Hassan MI. Protein aggregation, misfolding and consequential human neurodegenerative diseases. Int J Neurosci. 2017;127:1047\u201357. https:\/\/doi.org\/10.1080\/00207454.2017.1286339.","journal-title":"Int J Neurosci"},{"key":"3293_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.it.2008.10.002","volume":"30","author":"HU Lutz","year":"2009","unstructured":"Lutz HU, Binder CJ, Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol. 2009;30:43\u201351. https:\/\/doi.org\/10.1016\/j.it.2008.10.002.","journal-title":"Trends Immunol"},{"key":"3293_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.7555\/JBR.30.20150131","volume":"30","author":"J Wu","year":"2016","unstructured":"Wu J, Li L. Autoantibodies in Alzheimer\u2019s disease: potential biomarkers, pathogenic roles, and therapeutic implications. J Biomed Res. 2016;30:361\u201372. https:\/\/doi.org\/10.7555\/JBR.30.20150131.","journal-title":"J Biomed Res"},{"key":"3293_CR12","doi-asserted-by":"publisher","first-page":"850","DOI":"10.4103\/1673-5374.268971","volume":"15","author":"F Ciccocioppo","year":"2020","unstructured":"Ciccocioppo F, Bologna G, Ercolino E, Pierdomenico L, Simeone P, Lanuti P, Pieragostino D, Del Boccio P, Marchisio M, Miscia S. Neurodegenerative diseases as proteinopathies-driven immune disorders. Neural Regen Res. 2020;15:850\u20136. https:\/\/doi.org\/10.4103\/1673-5374.268971.","journal-title":"Neural Regen Res"},{"key":"3293_CR13","doi-asserted-by":"publisher","unstructured":"Deleidi M, Maetzler W. Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders., Int. J. Alzheimers. Dis. 2012 (2012) 391438. https:\/\/doi.org\/10.1155\/2012\/391438","DOI":"10.1155\/2012\/391438"},{"key":"3293_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00702-016-1632-4","volume":"124","author":"E Papu\u0107","year":"2017","unstructured":"Papu\u0107 E, Rejdak K. Anti-MAG autoantibodies are increased in Parkinson\u2019s disease but not in atypical parkinsonism. J Neural Transm. 2017;124:209\u201316. https:\/\/doi.org\/10.1007\/s00702-016-1632-4.","journal-title":"J Neural Transm"},{"key":"3293_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13195-018-0412-9","volume":"10","author":"S Agrawal","year":"2018","unstructured":"Agrawal S, Abud EM, Snigdha S, Agrawal A. IgM response against amyloid-beta in aging: a potential peripheral protective mechanism. Alzheimers Res Ther. 2018;10:81. https:\/\/doi.org\/10.1186\/s13195-018-0412-9.","journal-title":"Alzheimers Res Ther"},{"key":"3293_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3233\/JPD-230066","volume":"13","author":"EL Brown","year":"2023","unstructured":"Brown EL, Essigmann HT, Hoffman KL, Alexander AS, Newmark M, Jiang Z-D, Suescun J, Schiess MC, Hanis CL, DuPont HL. IgA-Biome profiles correlate with clinical Parkinson\u2019s Disease subtypes. J Parkinsons Dis. 2023;13:501\u201313. https:\/\/doi.org\/10.3233\/JPD-230066.","journal-title":"J Parkinsons Dis"},{"key":"3293_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13195-022-01062-z","volume":"14","author":"D Pocevi\u010di\u016bt\u0117","year":"2022","unstructured":"Pocevi\u010di\u016bt\u0117 D, Nu\u00f1ez-Diaz C, Roth B, Janelidze S, Giannisis A, Hansson O, Wennstr\u00f6m M, Bank TNB. Increased plasma and brain immunoglobulin A in Alzheimer\u2019s disease is lost in apolipoprotein E \u03b54 carriers. Alzheimers Res Ther. 2022;14:117. https:\/\/doi.org\/10.1186\/s13195-022-01062-z.","journal-title":"Alzheimers Res Ther"},{"key":"3293_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13024-017-0187-7","volume":"12","author":"T Brudek","year":"2017","unstructured":"Brudek T, Winge K, Folke J, Christensen S, Fog K, Pakkenberg B, Pedersen L\u00d8. Autoimmune antibody decline in Parkinson\u2019s disease and multiple system atrophy; a step towards immunotherapeutic strategies. Mol Neurodegener. 2017;12:44. https:\/\/doi.org\/10.1186\/s13024-017-0187-7.","journal-title":"Mol Neurodegener"},{"key":"3293_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.parkreldis.2021.05.001","volume":"87","author":"J Folke","year":"2021","unstructured":"Folke J, Rydbirk R, L\u00f8kkegaard A, Hejl A-M, Winge K, Starhof C, Salvesen L, Pedersen L\u00d8, Aznar S, Pakkenberg B, Brudek T. Cerebrospinal fluid and plasma distribution of anti-\u03b1-synuclein IgMs and IgGs in multiple system atrophy and Parkinson\u2019s disease. Parkinsonism Relat Disord. 2021;87:98\u2013104. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.05.001.","journal-title":"Parkinsonism Relat Disord"},{"key":"3293_CR20","doi-asserted-by":"publisher","first-page":"6554","DOI":"10.3390\/ijms23126554","volume":"23","author":"J Folke","year":"2022","unstructured":"Folke J, Bergholt E, Pakkenberg B, Aznar S, Brudek T. Alpha-synuclein autoimmune decline in Prodromal multiple system atrophy and Parkinson\u2019s Disease. Int J Mol Sci. 2022;23:6554. https:\/\/doi.org\/10.3390\/ijms23126554.","journal-title":"Int J Mol Sci"},{"key":"3293_CR21","doi-asserted-by":"crossref","unstructured":"Jianping L, Zhibing Y, Wei Q, Zhikai C, Jie X, Jinbiao L. Low avidity and level of serum Anti-A\u03b2 antibodies in Alzheimer Disease, Alzheimer dis. Assoc Disord 20 (2006). https:\/\/journals.lww.com\/alzheimerjournal\/Fulltext\/2006\/07000\/Low_Avidity_and_Level_of_Serum_Anti_A__Antibodies.1.aspx","DOI":"10.1097\/00002093-200607000-00001"},{"key":"3293_CR22","doi-asserted-by":"publisher","unstructured":"Folke J, Ferreira N, Brudek T, Borghammer P, Van Den Berge N. Passive Immunization in Alpha-Synuclein Preclinical Animal models. Biomolecules. 2022;12. https:\/\/doi.org\/10.3390\/biom12020168.","DOI":"10.3390\/biom12020168"},{"key":"3293_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM. 2 investigators, Donanemab in early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"key":"3293_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13:80. https:\/\/doi.org\/10.1186\/s13195-021-00813-8.","journal-title":"Alzheimers Res Ther"},{"key":"3293_CR25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601. https:\/\/doi.org\/10.1002\/mds.26424.","journal-title":"Mov Disord"},{"key":"3293_CR26","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, D\u00fcrr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670\u20136. https:\/\/doi.org\/10.1212\/01.wnl.0000324625.00404.15.","journal-title":"Neurology"},{"key":"3293_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O\u2019Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88\u2013100. https:\/\/doi.org\/10.1212\/WNL.0000000000004058.","journal-title":"Neurology"},{"key":"3293_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimer\u2019s Dement"},{"key":"3293_CR29","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.3389\/fimmu.2019.02253","volume":"10","author":"J Folke","year":"2019","unstructured":"Folke J, Rydbirk R, L\u00f8kkegaard A, Salvesen L, Hejl A-M, Starhof C, Bech S, Winge K, Christensen S, Pedersen L\u00d8, Aznar S, Pakkenberg B, Brudek T. Distinct autoimmune Anti-\u03b1-Synuclein antibody patterns in multiple system atrophy and Parkinson\u2019s Disease. Front Immunol. 2019;10:2253. https:\/\/doi.org\/10.3389\/fimmu.2019.02253.","journal-title":"Front Immunol"},{"key":"3293_CR30","unstructured":"Fox J, Weisberg S. An R companion to Applied Regression, Second Edi. SAGE; 2011."},{"key":"3293_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/bimj.200810425","volume":"50","author":"T Hothorn","year":"2008","unstructured":"Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biom J. 2008;50:346\u201363. https:\/\/doi.org\/10.1002\/bimj.200810425.","journal-title":"Biom J"},{"key":"3293_CR32","unstructured":"Wei T, Simko V. R package corrplot: visualization of a correlation matrix, (2017). https:\/\/github.com\/taiyun\/corrplot"},{"key":"3293_CR33","unstructured":"Team RC. R: A Language and Environment for Statistical Computing, (2014)."},{"key":"3293_CR34","doi-asserted-by":"crossref","unstructured":"Nielsen AK, Folke J, Owczarek S, Svenstrup K, Winge K, Pakkenberg B, Aznar S, Brudek T. TDP-43 specific autoantibody decline in amyotrophic lateral sclerosis: implications for immunotherapeutic strategies, Neurol. Neuroimmunol. Neuroinflammation In; 2020.","DOI":"10.1212\/NXI.0000000000000937"},{"key":"3293_CR35","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1212\/wnl.57.5.801","volume":"57","author":"Y Du","year":"2001","unstructured":"Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel W, Farlow M, Paul S. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001;57:801\u20135. https:\/\/doi.org\/10.1212\/wnl.57.5.801.","journal-title":"Neurology"},{"key":"3293_CR36","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1212\/01.wnl.0000242630.52203.8f","volume":"67","author":"JE Galvin","year":"2006","unstructured":"Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology. 2006;67:1605\u201311. https:\/\/doi.org\/10.1212\/01.wnl.0000242630.52203.8f.","journal-title":"Neurology"},{"key":"3293_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00401-007-0336-0","volume":"115","author":"T Lashley","year":"2008","unstructured":"Lashley T, Holton JL, Gray E, Kirkham K, O\u2019Sullivan SS, Hilbig A, Wood NW, Lees AJ, Revesz T. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson\u2019s disease patients. Acta Neuropathol. 2008;115:417\u201325. https:\/\/doi.org\/10.1007\/s00401-007-0336-0.","journal-title":"Acta Neuropathol"},{"key":"3293_CR38","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci off J Soc Neurosci. 2010;30:7281\u20139. https:\/\/doi.org\/10.1523\/JNEUROSCI.0490-10.2010.","journal-title":"J Neurosci off J Soc Neurosci"},{"key":"3293_CR39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","volume":"65","author":"VM Nemani","year":"2010","unstructured":"Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66\u201379. https:\/\/doi.org\/10.1016\/j.neuron.2009.12.023.","journal-title":"Neuron"},{"key":"3293_CR40","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.ajpath.2011.04.013","volume":"179","author":"N Stefanova","year":"2011","unstructured":"Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK. Toll-like receptor 4 promotes \u03b1-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol. 2011;179:954\u201363. https:\/\/doi.org\/10.1016\/j.ajpath.2011.04.013.","journal-title":"Am J Pathol"},{"key":"3293_CR41","doi-asserted-by":"publisher","first-page":"110090","DOI":"10.1016\/j.celrep.2021.110090","volume":"38","author":"MM Alam","year":"2022","unstructured":"Alam MM, Yang D, Li X-Q, Liu J, Back TC, Trivett A, Karim B, Barbut D, Zasloff M, Oppenheim JJ. Alpha synuclein, the culprit in Parkinson disease, is required for normal immune function. Cell Rep. 2022;38:110090. https:\/\/doi.org\/10.1016\/j.celrep.2021.110090.","journal-title":"Cell Rep"},{"key":"3293_CR42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaut.2007.07.007","volume":"29","author":"HU Lutz","year":"2007","unstructured":"Lutz HU. Homeostatic roles of naturally occurring antibodies: an overview. J Autoimmun. 2007;29:287\u201394. https:\/\/doi.org\/10.1016\/j.jaut.2007.07.007.","journal-title":"J Autoimmun"},{"key":"3293_CR43","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3389\/fneur.2018.00815","volume":"9","author":"KM Scott","year":"2018","unstructured":"Scott KM, Kouli A, Yeoh SL, Clatworthy MR, Williams-Gray CH. A systematic review and Meta-analysis of alpha synuclein auto-antibodies in Parkinson\u2019s Disease. Front Neurol. 2018;9:815. https:\/\/doi.org\/10.3389\/fneur.2018.00815.","journal-title":"Front Neurol"},{"key":"3293_CR44","unstructured":"Lundbeck AS, Lundbeck H. A\/S: Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD\/PD 2024 conference on neurodegenerative disorders - Inderes, (2024) 1\u20133. https:\/\/www.inderes.dk\/en\/releases\/h-lundbeck-as-lundbeck-presents-encouraging-results-from-the-lu-af82422-trial-for-multiple-system-atrophy-at-the-international-adpd-2024-conference-on-neurodegenerative-disorders"},{"key":"3293_CR45","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1021\/acschemneuro.7b00063","volume":"8","author":"I Horvath","year":"2017","unstructured":"Horvath I, Iashchishyn IA, Forsgren L, Morozova-Roche LA. Immunochemical detection of \u03b1-Synuclein autoantibodies in Parkinson\u2019s Disease: correlation between plasma and cerebrospinal fluid levels. ACS Chem Neurosci. 2017;8:1170\u20136. https:\/\/doi.org\/10.1021\/acschemneuro.7b00063.","journal-title":"ACS Chem Neurosci"},{"key":"3293_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/JAD-2011-110221","volume":"26","author":"W Maetzler","year":"2011","unstructured":"Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, Gasser T, H\u00f6rnig S, Langkamp M. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis. 2011;26:171\u20139. https:\/\/doi.org\/10.3233\/JAD-2011-110221.","journal-title":"J Alzheimers Dis"},{"key":"3293_CR47","doi-asserted-by":"publisher","first-page":"e68996","DOI":"10.1371\/journal.pone.0068996","volume":"8","author":"M Maftei","year":"2013","unstructured":"Maftei M, Thurm F, Schnack C, Tumani H, Otto M, Elbert T, Kolassa I-T, Przybylski M, Manea M, von Arnim CAF. Increased levels of antigen-bound \u03b2-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer\u2019s disease patients. PLoS ONE. 2013;8:e68996. https:\/\/doi.org\/10.1371\/journal.pone.0068996.","journal-title":"PLoS ONE"},{"key":"3293_CR48","doi-asserted-by":"publisher","unstructured":"Liu Y-H, Wang J, Li Q-X, Fowler CJ, Zeng F, Deng J, Xu Z-Q, Zhou H-D, Doecke JD, Villemagne VL, Lim YY, Masters CL, Wang Y-J. Association of naturally occurring antibodies to \u03b2-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer\u2019s disease. Sci Adv. 2021;7. https:\/\/doi.org\/10.1126\/sciadv.abb0457.","DOI":"10.1126\/sciadv.abb0457"},{"key":"3293_CR49","doi-asserted-by":"publisher","first-page":"fcad060","DOI":"10.1093\/braincomms\/fcad060","volume":"5","author":"KM Scott","year":"2023","unstructured":"Scott KM, Chong YT, Park S, Wijeyekoon RS, Hayat S, Mathews RJ, Fitzpatrick Z, Tyers P, Wright G, Whitby J, Barker RA, Hu MT, Williams-Gray CH, Clatworthy MR. B lymphocyte responses in Parkinson\u2019s disease and their possible significance in disease progression. Brain Commun. 2023;5:fcad060. https:\/\/doi.org\/10.1093\/braincomms\/fcad060.","journal-title":"Brain Commun"},{"key":"3293_CR50","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1038\/s41467-021-22479-4","volume":"12","author":"K Kim","year":"2021","unstructured":"Kim K, Wang X, Ragonnaud E, Bodogai M, Illouz T, DeLuca M, McDevitt RA, Gusev F, Okun E, Rogaev E, Biragyn A. Therapeutic B-cell depletion reverses progression of Alzheimer\u2019s disease. Nat Commun. 2021;12:2185. https:\/\/doi.org\/10.1038\/s41467-021-22479-4.","journal-title":"Nat Commun"},{"key":"3293_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2012.00066","volume":"3","author":"C Gr\u00f6nwall","year":"2012","unstructured":"Gr\u00f6nwall C, Vas J, Silverman GJ. Protective roles of natural IgM antibodies. Front Immunol. 2012;3:1\u201310. https:\/\/doi.org\/10.3389\/fimmu.2012.00066.","journal-title":"Front Immunol"},{"key":"3293_CR52","doi-asserted-by":"publisher","unstructured":"Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Structure, function, and therapeutic use of IgM antibodies. Antibodies (Basel Switzerland). 2020;9. https:\/\/doi.org\/10.3390\/antib9040053.","DOI":"10.3390\/antib9040053"},{"key":"3293_CR53","doi-asserted-by":"publisher","first-page":"595535","DOI":"10.3389\/fimmu.2020.595535","volume":"11","author":"K Jones","year":"2020","unstructured":"Jones K, Savulescu AF, Brombacher F, Hadebe S, Immunoglobulin M. Health and diseases: how far have we come and what Next? Front Immunol. 2020;11:595535. https:\/\/doi.org\/10.3389\/fimmu.2020.595535.","journal-title":"Front Immunol"},{"key":"3293_CR54","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.neuroscience.2021.03.006","volume":"463","author":"A Albus","year":"2021","unstructured":"Albus A, Kronimus Y, Neumann S, Vidovic N, Frenzel A, Kuhn P, Seifert M, Ziehm T, van der Wurp H, Dodel R. Effects of a Multimerized recombinant autoantibody against Amyloid-\u03b2. Neuroscience. 2021;463:355\u201369. https:\/\/doi.org\/10.1016\/j.neuroscience.2021.03.006.","journal-title":"Neuroscience"},{"key":"3293_CR55","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1084\/jem.191.7.1253","volume":"191","author":"MR Ehrenstein","year":"2000","unstructured":"Ehrenstein MR, Cook HT, Neuberger MS. Deficiency in serum immunoglobulin (ig)m predisposes to Development of Igg autoantibodies. J Exp Med. 2000;191:1253\u20138. https:\/\/doi.org\/10.1084\/jem.191.7.1253.","journal-title":"J Exp Med"},{"key":"3293_CR56","doi-asserted-by":"publisher","first-page":"2032057","DOI":"10.1155\/2020\/2032057","volume":"2020","author":"Y Li","year":"2020","unstructured":"Li Y, Jin L, Chen T. The effects of secretory IgA in the Mucosal Immune System. Biomed Res Int. 2020;2020:2032057. https:\/\/doi.org\/10.1155\/2020\/2032057.","journal-title":"Biomed Res Int"},{"key":"3293_CR57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41385-019-0227-4","volume":"13","author":"O Pabst","year":"2020","unstructured":"Pabst O, Slack E. IgA and the intestinal microbiota: the importance of being specific. Mucosal Immunol. 2020;13:12\u201321. https:\/\/doi.org\/10.1038\/s41385-019-0227-4.","journal-title":"Mucosal Immunol"},{"key":"3293_CR58","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00253-023-12410-w","volume":"107","author":"J Shi","year":"2023","unstructured":"Shi J, Wang Y, Chen D, Xu X, Li W, Li K, He J, Su W, Luo Q. The alteration of intestinal mucosal \u03b1-synuclein expression and mucosal microbiota in Parkinson\u2019s disease. Appl Microbiol Biotechnol. 2023;107:1917\u201329. https:\/\/doi.org\/10.1007\/s00253-023-12410-w.","journal-title":"Appl Microbiol Biotechnol"},{"key":"3293_CR59","doi-asserted-by":"publisher","unstructured":"Chandra R, Hiniker A, Kuo Y-M, Nussbaum RL, Liddle RA. \u03b1-Synuclein in gut endocrine cells and its implications for Parkinson\u2019s disease. JCI Insight. 2017;2. https:\/\/doi.org\/10.1172\/jci.insight.92295.","DOI":"10.1172\/jci.insight.92295"},{"key":"3293_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3988\/jcn.2016.12.2.147","volume":"12","author":"G \u00c7amc\u0131","year":"2016","unstructured":"\u00c7amc\u0131 G, O\u011fuz S. Association between Parkinson\u2019s Disease and Helicobacter Pylori. J Clin Neurol. 2016;12:147\u201350. https:\/\/doi.org\/10.3988\/jcn.2016.12.2.147.","journal-title":"J Clin Neurol"},{"key":"3293_CR61","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00401-023-02562-4","volume":"145","author":"W Peelaerts","year":"2023","unstructured":"Peelaerts W, Mercado G, George S, Villumsen M, Kasen A, Aguileta M, Linstow C, Sutter AB, Kuhn E, Stetzik L, Sheridan R, Bergkvist L, Meyerdirk L, Lindqvist A, Gavis MLE, Van den Haute C, Hultgren SJ, Baekelandt V, Pospisilik JA, Brudek T, Aznar S, Steiner JA, Henderson MX, Brundin L, Ivanova MI, Hannan TJ, Brundin P. Urinary tract infections trigger synucleinopathy via the innate immune response. Acta Neuropathol. 2023;145:541\u201359. https:\/\/doi.org\/10.1007\/s00401-023-02562-4.","journal-title":"Acta Neuropathol"},{"key":"3293_CR62","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12974-023-02720-1","volume":"20","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Tong Q, Yuan Y, Song X, Jiang W, Wang Y, Li W, Li Y, Zhang K. \u03b1-Synuclein induces prodromal symptoms of Parkinson\u2019s disease via activating TLR2\/MyD88\/NF-\u03baB pathway in Schwann cells of vagus nerve in a rat model. J Neuroinflammation. 2023;20:36. https:\/\/doi.org\/10.1186\/s12974-023-02720-1.","journal-title":"J Neuroinflammation"},{"key":"3293_CR63","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim S, Kwon S-H, Kam T-I, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, Shen C, Lee H, Kulkarni S, Pasricha PJ, Lee G, Pomper MG, Dawson VL, Dawson TM, Ko HS. Transneuronal Propagation of pathologic \u03b1-Synuclein from the gut to the Brain models Parkinson\u2019s Disease. Neuron. 2019;103:627\u2013e6417. https:\/\/doi.org\/10.1016\/j.neuron.2019.05.035.","journal-title":"Neuron"},{"key":"3293_CR64","doi-asserted-by":"publisher","unstructured":"Wang P, Luo M, Zhou W, Jin X, Xu Z, Yan S, Li Y, Xu C, Cheng R, Huang Y, Lin X, Yao L, Nie H, Jiang Q. Global characterization of Peripheral B cells in Parkinson\u2019s disease by single-cell RNA and BCR sequencing. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.814239.","DOI":"10.3389\/fimmu.2022.814239"},{"key":"3293_CR65","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41586-020-2886-4","volume":"587","author":"Z Fitzpatrick","year":"2020","unstructured":"Fitzpatrick Z, Frazer G, Ferro A, Clare S, Bouladoux N, Ferdinand J, Tuong ZK, Negro-Demontel ML, Kumar N, Suchanek O, Tajsic T, Harcourt K, Scott K, Bashford-Rogers R, Helmy A, Reich DS, Belkaid Y, Lawley TD, McGavern DB, Clatworthy MR. Gut-educated IgA plasma cells defend the meningeal venous sinuses. Nature. 2020;587:472\u20136. https:\/\/doi.org\/10.1038\/s41586-020-2886-4.","journal-title":"Nature"},{"key":"3293_CR66","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A. The Amyloid-\u03b2 pathway in Alzheimer\u2019s Disease. Mol Psychiatry. 2021;26:5481\u2013503. https:\/\/doi.org\/10.1038\/s41380-021-01249-0.","journal-title":"Mol Psychiatry"},{"key":"3293_CR67","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/mds.29329","volume":"38","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio L, Weber S, Farris CM, Dakna M, Lang E, Wicke T, Ma Y, Starke M, Ebentheuer J, Sixel-D\u00f6ring F, Muntean M-L, Schade S, Trenkwalder C, Soto C, Mollenhauer B. Accurate detection of \u03b1-Synuclein seeds in cerebrospinal fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and patients with Parkinson\u2019s Disease in the DeNovo Parkinson (DeNoPa) Cohort. Mov Disord. 2023;38:567\u201378. https:\/\/doi.org\/10.1002\/mds.29329.","journal-title":"Mov Disord"},{"key":"3293_CR68","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/mds.29766","volume":"39","author":"A Kluge","year":"2024","unstructured":"Kluge A, Schaeffer E, Bunk J, Sommerauer M, R\u00f6ttgen S, Schulte C, Roeben B, von Thaler A-K, Welzel J, Lucius R, Heinzel S, Xiang W, Eschweiler GW, Maetzler W, Suenkel U, Berg D. Detecting misfolded \u03b1-Synuclein in blood years before the diagnosis of Parkinson\u2019s Disease. Mov Disord. 2024;39:1289\u201399. https:\/\/doi.org\/10.1002\/mds.29766.","journal-title":"Mov Disord"},{"key":"3293_CR69","doi-asserted-by":"publisher","unstructured":"Reyneveld GI, Savelkoul HFJ, Parmentier HK. Current understanding of natural antibodies and exploring the possibilities of Modulation using Veterinary models. Rev Front Immunol. 2020;11. https:\/\/doi.org\/10.3389\/fimmu.2020.02139.","DOI":"10.3389\/fimmu.2020.02139"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-024-03293-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-024-03293-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-024-03293-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:29:23Z","timestamp":1781605763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12974-024-03293-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3293"],"URL":"https:\/\/doi.org\/10.1186\/s12974-024-03293-3","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by the Danish National Committee on Health Research Ethics, Copenhagen Regional Area (j.no.: H-15016232) and the Danish Data Protection Agency (j.no.: P-2020-937). All participants gave written consent for inclusion in the biobanks according to the World Medical Association Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}